Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tradr 2X Short TSLA Daily ETF
TSLQ
5
ProShares UltraPro Short S&P500 ETF
SPXU
US Stock MarketDetailed Quotes
CMPS COMPASS Pathways
- 3.770
- -0.110-2.84%
Close Apr 29 16:00 ET
- 3.810
- +0.040+1.06%
Pre 08:00 ET
350.04MMarket Cap-1.64P/E (TTM)
4.000High3.735Low453.04KVolume3.870Open3.880Pre Close1.73MTurnover0.63%Turnover RatioLossP/E (Static)92.85MShares9.63052wk High2.26P/B271.46MFloat Cap2.49052wk Low--Dividend TTM72.00MShs Float61.690Historical High--Div YieldTTM6.83%Amplitude2.490Historical Low3.811Avg Price1Lot Size
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
COMPASS Pathways Stock Forum
Major Depression Breakthrough? Phase 3 Psilocybin Trial Completes Dosing, June Results Awaited
Compass Pathways Announces Dosing Complete for All Participants in Part a of Phase 3 Comp005 Trial of Comp360 Psilocybin for Treatment-Resistant Depression!
Compass Pathways PLC - Top-Line 6-Week Primary Endpoint Results Expected in Late June
Breakthrough Depression Treatment Reaches Critical Phase 3 Milestone: COMP360 Psilocybin Trial Fully Enrolled
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Wednesday, 26th March at 6:30 am
Highlights:
• Screening closed for all sites and final participants being scheduled for dosing
• On track for top-line 6-week primary endpoint results in late Q2
Compass Pathways plc (NASDAQ: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation,...
Breakthrough: Single Dose Psilocybin Fights Depression for 189 Days, New Study Shows
Can Compass Pathways' $140M Cash Infusion Offset Growing Losses in Psychedelic Treatment Race?
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
No comment yet